Labcorp (LH)
(Delayed Data from NYSE)
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Should Value Investors Buy LabCorp (LH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LH vs. CNMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Pacific Biosciences (PACB)-RCIGM Tie Up for Sequencing Research
by Zacks Equity Research
Pacific Biosciences' (PACB) latest research tie-up is likely to use HiFi Sequencing data on some of the most difficult cases of rare pediatric disease and provide insights into the treatment journey.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
LabCorp (LH), Molecular Loop Team Up for COVID-19 Test Research
by Zacks Equity Research
The SARS-CoV-2 Research Sequencing Panel will help LabCorp (LH) sequence thousands of complete coronavirus genomes each week from positive patient samples.
LabCorp (LH) Boosts Precision Oncology With INSIGHT NGS Launch
by Zacks Equity Research
LabCorp (LH) enables evidence-based, personalized treatment suggestions based on the genomic profiling of a patient's solid tumor with the launch of new test.
LabCorp's (LH) Pixel Home Collection Kit Now in WBA Stores
by Zacks Equity Research
According to LabCorp (LH), the on-demand delivery option is useful for individuals showing symptoms of COVID-19 infection who want to be tested without potentially infecting others.
3 Medical Diagnostics Stocks in Focus on Long-Term Potential
by Riya Anand
MedTech testing stocks like Quest Diagnostics Incorporated (DGX), Thermo Fisher Scientific, Inc. (TMO) and Laboratory Corporation of America Holdings (LH) are likely to survive post-pandemic.
Myriad Genetics (MYGN) Sells myPath to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.
Quest Diagnostics (DGX) New Pact Targets Health Inequity Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with SAHRC will help improve the health and quality of lives of underserved communities.
LabCorp's (LH) New Bioanalytical Lab to Boost APAC Operation
by Zacks Equity Research
The new laboratory by LabCorp (LH) is set to enable faster data turnaround for early phase trials in Asia-Pacific markets.
LabCorp's (LH) Pixel Kit Gets EUA for Younger Population
by Zacks Equity Research
LabCorp (LH) becomes the first major commercial laboratory to offer a COVID-19 PCR Test Home Collection Kit for children and adolescents.
Quest Diagnostics (DGX) Expands COVID-19 Test Eligibility
by Zacks Equity Research
This zero out-of-pocket option applies to Quest Diagnostics' (DGX) molecular laboratory (PCR/NAAT) as well as rapid antigen testing.
QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
by Zacks Equity Research
LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised
by Zacks Equity Research
LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.
LabCorp (LH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 20.08% and 7.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Apr 29 Earnings Roster: TMO, BAX & More
by Trina Mukherjee
The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Why Earnings Season Could Be Great for LabCorp (LH)
by Zacks Equity Research
LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
LabCorp (LH) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.
LabCorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why LabCorp (LH) Could Beat Earnings Estimates Again
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.
Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.